ClinicalTrials.gg
RecruitingNCT07521046RopeRuxUpdated Oct 19, 2026

Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis

A Phase 1 interventional study of ropeginterferon alfa- 2b and Ruxolitinib in Myelofibrosis, sponsored by University of Utah. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by University of Utah · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 19, 2026Now RecruitingStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.

Planned enrollment
39th of 50
15 · median 45
Started
2026
with 4 others
Phase 1
12 of 50
2 open now
Primary completion
2029-08
later than 10 of 14 live
Registered
50th of 50
by date

Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one is the 39th largest by planned enrollment, is one of 5 that started in 2026, is one of 12 in phase 1, reaches primary completion later than 10 of the 14 other live ones, and was the 50th registered.

Primary Myelofibrosis

628 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing ruxolitinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in treating patients with Myelofibrosis.

03

Conditions studied

  • Myelofibrosis

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subject aged ≥ 18 years.
  • Diagnosed with PMF, post-PV MF, or post-ET MF per WHO 2016 or 2022 criteria, bearing one of these MPN phenotype defining mutations (JAK2, CALR, and MPL), and with a DIPSS score of low, intermediate-1 or intermediate-2.
  • Subjects must be already on standard of care ruxolitinib per the treating physician for at least 3 months or more, and on a stable dose for at least 6 weeks prior to screening.

Note: Conversion between immediate -released (IR) ruxolitinib to an equivalent dose of extended -release (XR) ruxolitinib should not be considered a dose change.

  • Subjects must have spleen volume of > 450ml by either MRI or CT scan
  • Subject must have a JAK2, CALR, or MPL allelic burden of ≥20% at screening

    --Prior treatment for PV or ET with hydroxyurea or ruxolitinib is allowed. If the patient was on pegylated interferon in the past, the progression from PV/ ET to post-PV/ET MF must not have occurred while on pegylated interferon therapy.

  • Performance Status ≤ 2.
  • Adequate organ function as defined as:

    --Hematologic:

    ---WBC count ≥ 4 x 109/L

    • (ANC) ≥1500/mm3
    • count ≥ 75,000/mm3
    • ≥ 8 g/dL

      --Hepatic:

    • Total ≤ 1.5x institutional (ULN)
    • (SGOT)/ALT(SGPT) ≤ 3 × institutional ULN

      --Renal:

    • Estimated ≥ 50 mL/min by Cockcroft-Gault formula
  • Recovery to baseline or ≤ Grade 1 v 6.0 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy per the treating investigator.
  • Participants must adhere to the following sex and /barrier requirements:

    • If participant is of , they must have a negative pregnancy test
    • For participants of non-childbearing potential: The status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
    • \< 50 years of age:

      ---Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and

      ---Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution

      --≥ 50 years of age:

      ---Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or

      ---Had radiation-induced menopause with last menses >1 year ago; or

      ---Had chemotherapy-induced menopause with last menses >1 year ago

      ---Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution

    • Participants of childbearing potential and participants with a sexual partner of childbearing potential must agree to use a highly effective method of contraception and lactation requirements as described in Sections 6.4.1 and 6.4.3.
  • Able to provide and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion criteria

Exclusion Criteria:

  • PV or ET patients who progressed while on pegylated interferon or ropeginterferon therapy.
  • Receiving other agents.
  • Existence of, or history of severe psychiatric disorders, particularly severe depression, suicidal ideation, or suicide attempt (Patients with pre-existing depression who are well-controlled and on stable doses of antidepressants are eligible).
  • Evidence of severe retinopathy or eye disease.
  • History or presence of active serious or untreated disease.
  • History of solid organ transplant.
  • Liver cirrhosis score B or C.

    • 5% blasts in peripheral blood or bone marrow.
  • Prior systemic anti-cancer therapy or any investigational therapy ≤ 14 days or within five half-lives prior to starting study treatment, whichever is shorter.
  • Major surgery 4 weeks prior to starting study drug or who have not fully recovered from major surgery.
  • The diagnosis of another which, in the investigator's opinion, is likely to significantly impact study participation.
  • Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:

    • Cardiovascular disorders:

      • Uncontrolled hypertension, in the opinion of the investigator
      • Congestive heart failure Class II or greater, unstable angina pectoris, serious cardiac arrhythmias.
      • Stroke or myocardial infarction within the past 3 months
      • Significant coronary stenosis, in the opinion of the investigator
      • prolongation defined as a QTcF > 500 ms.
      • Known congenital long QT.
    • Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, [subjects may not receive the drug through a feeding tube], social/ psychological issues, etc.)
  • Known infection with a detectable viral load within 6 months of the anticipated start of treatment.

Note: Subjects on effective antiretroviral therapy with an undetectable viral load within 6 months of the anticipated start of treatment are eligible for this trial.

-Active infection requiring systemic therapy, including, but not limited to: tuberculosis (clinical evaluation that includes clinical history, physical examination, radiographic findings, and TB testing in line with local practice), (known positive HBV surface antigen (HBsAg) result), or .

Note: Subjects with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Subjects positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.

  • Medical, psychiatric, cognitive, or other conditions that may compromise the subject's ability to understand the subject information, give , comply with the study protocol or complete the study.
  • Known prior severe to investigational product (IP) or any component in its formulations ( v 6.0 Grade ≥ 3).
  • Subjects taking prohibited medications as described in Section 7.8. A of prohibited medications for a period of at least five half-lives or as clinically indicated should occur before the start of treatment.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Treatment: All Patients

    This study will investigate the safety and tolerability of ropeginterferon alfa- 2b added on to standard of care ruxolitinib.

    Drug: ropeginterferon alfa- 2b · Drug: Ruxolitinib

Interventions

  • Ropeginterferon alfa- 2b will be administered as a subcutaneous injection every two weeks.

  • Ruxolitinib will be administered per standard of care.

06

What researchers measure

Primary outcomes

  1. The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type

    To assess the safety and tolerability of ropeginterferon alfa- 2b add-on to ruxolitinib in the study population.

    Time frame: 2 years

  2. The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by severity (as defined by the NIH CTCAE, version 6.0).

    To assess the safety and tolerability of ropeginterferon alfa- 2b add-on to ruxolitinib in the study population.

    Time frame: 2 years

  3. The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by seriousness.

    To assess the safety and tolerability of ropeginterferon alfa- 2b add-on to ruxolitinib in the study population.

    Time frame: 2 years

  4. The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by duration.

    To assess the safety and tolerability of ropeginterferon alfa- 2b add-on to ruxolitinib in the study population.

    Time frame: 2 years

  5. The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by the relationship to study treatment.

    To assess the safety and tolerability of ropeginterferon alfa- 2b add-on to ruxolitinib in the study population.

    Time frame: 2 years

Secondary outcomes

  1. The proportion of subjects who achieve >50% reduction in JAK2 V617F mutation burden.

    To assess the incidence of patients who achieve \>50% reduction in JAK2 V617F mutation burden.

    Time frame: 2 years

  2. Change in JAK2, CALR, MPL mutations allelic burden.

    To assess the rate of reduction of JAK2, CALR, MPL mutations allelic burden.

    Time frame: 2 years

  3. The proportion of subjects who achieve a 25% decrease in spleen volume by 24 weeks from initiation of combination treatment.

    To assess the rate of 25% spleen volume reduction at 24 weeks of the combination (Abdominal MRI will be done for spleen size measurement).

    Time frame: 24 weeks

  4. Change in quality of life Myeloproliferative Neoplasm (MPN) Symptom Questionnaire from baseline and throughout treatment.

    To assess the change in the quality of life MPN Symptom Questionnaire score. The MPN Symptom questionnaire consists of 10 questions asking patients to rate their symptoms on a scale of 1 to 10, with 0 being no symptoms and 10 being the worst symptoms.

    Time frame: 2 years

  5. The proportion of subjects who progress to blastic phase and secondary acute myeloid leukemia at 2 years post-treatment.

    To assess the rate of blastic transformation.

    Time frame: 2 years

  6. The proportion of subjects who have a change in bone marrow fibrosis grade.

    To assess the rate of change in myelofibrosis (MF) grade (MF grade 0 to 3, the higher the worse).

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Aug 2029, 36 months after the start.

Of 68 phase 1 interventional studies under Primary Myelofibrosis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 103. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2026
First posted
Apr 9, 2026
StartActual
Aug 21, 2026
Primary completionEst.
Aug 2029
CompletionEst.
Aug 2030
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 1, 2026
Sites
Huntsman Cancer Institute at University of Utah is now Recruiting
Oct 1, 2026
Start date
Aug 2026→Aug 21, 2026 (actual)
moved 2 times, Oct 1, 2026 – Oct 19, 2026
Eligibility
6 inclusion criteria edited, 1 added; 1 exclusion criterion edited, 1 added
What changed in the criteria
Inclusion criteria
  • AddedNote: Conversion between immediate -released (IR) ruxolitinib to an equivalent dose of extended -release (XR) ruxolitinib should not be considered a dose change.
  • Edited--Hematologic:
  • Edited---WBC count ≥ 4 x 109/L
  • Edited--Hepatic:
  • Edited---Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN)
  • Edited---AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN
  • Edited--Renal:
Exclusion criteria
  • EditedLiver cirrhosis Child-Pugh score B or C. -≥ 5% blasts in peripheral blood or bone marrow.
  • Added5% blasts in peripheral blood or bone marrow.
Oct 19, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedChange in quality of life Myeloproliferative Neoplasm Symptom Assessment Form Total(MPN) Symptom Score (MPN-SAF TSS)Questionnaire from baseline and throughout treatment.Time frame: 2 years
Oct 19, 2026
Title
Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)
Oct 1, 2026
Show all 2 updates
  1. Oct 19, 2026
    Start date Oct 2026→Aug 21, 2026 (now actual)
    Eligibility 6 inclusion criteria edited, 1 added; 1 exclusion criterion edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • AddedNote: Conversion between immediate -released (IR) ruxolitinib to an equivalent dose of extended -release (XR) ruxolitinib should not be considered a dose change.
    • Edited--Hematologic:
    • Edited---WBC count ≥ 4 x 109/L
    • Edited--Hepatic:
    • Edited---Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN)
    • Edited---AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN
    • Edited--Renal:
    Exclusion criteria
    • EditedLiver cirrhosis Child-Pugh score B or C. -≥ 5% blasts in peripheral blood or bone marrow.
    • Added5% blasts in peripheral blood or bone marrow.
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in quality of life Myeloproliferative Neoplasm Symptom Assessment Form Total(MPN) Symptom Score (MPN-SAF TSS)Questionnaire from baseline and throughout treatment.Time frame: 2 years
    + 1 other change: verification date
  2. Oct 1, 2026
    Not yet recruiting→Recruiting
    Huntsman Cancer Institute at University of Utah is now Recruiting
    Start date Aug 2026→Oct 2026
    Title Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07521046
Lead sponsor
University of Utah
Collaborators
PharmaEssentia
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
Aug 21, 2026
Primary completion
Aug 2029 (estimated)
Completion
Aug 2030 (estimated)
Last update
Oct 19, 2026

Study contacts

Nicole Fisher
Contact
nicole.fisher@hci.utah.edu
801-587-7604
Tsewang Tashi, MD
Contact
u0820872@utah.edu
801-585-0255
Tsewang Tashi, MD
principal investigator · Huntsman Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ropeginterferon alfa-2b · Ruxolitinib

Start the discussion